Hemophilia in Children: Clinical Manifestations, Diagnosis, and Advances in Comprehensive Management
1. Muktarali's daughter Begimai
ORCID 0009-0004-5619-0461
2. Ruwa Tahir
3. Ifrah Nabi
(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)
Abstract
This article discusses the inherited bleeding disorder hemophilia that results from improper functioning of the clotting factors VIII (hemophilia A) or IX (hemophilia B). The disorder could manifest in children with repeated bleeding episodes, hemarthrosis, muscle hematoma, and severe bleeding episodes. With timely diagnosis and adequate therapy, it is possible to prevent complications, maintain the joint function, and enhance the quality of life. The purpose of this review is to analyze the studies regarding the clinical manifestations of hemophilia, approaches, complications, and treatment methods.
Relevant articles, clinical studies, medical international guidelines, and databases were analyzed to determine the effectiveness of treatment of hemophilia in children. The severity of hemophilia is determined by the residual activity of the clotting factor.
Diagnosis is based on both clinical evaluation and tests. One of the most advanced therapies is prophylactic replacement therapy using clotting factors to prevent bleeding episodes as well as joint damages. Besides, with the emergence of emicizumab, patients suffering from hemophilia A with inhibitors of factor VIII received new therapeutic options.
Keywords: Hemophilia, Hemophilia A, Hemophilia B, Children, Coagulation disorders, Hemarthrosis, Diagnosis, Prophylactic treatment.
Introduction
Hemophilia is a genetic bleeding disorder that occurs due to a deficiency or malfunction of certain clotting factors leading to disruption in the process of clot formation, which results in prolonged bleeding. This disease can be divided into hemophilia A, which is caused by lack of factor VIII, and hemophilia B, caused by deficiency of factor IX. The two disorders are transmitted in an X-linked recessive way and affect mostly men, but women are also affected (at least to some extent) by bleeding problems [1,2].Hemophilia is a big issue in pediatrics because the episodes of bleeding may start in infants and children. The severity of hemophilia depends on the amount of the defective coagulation factor that has some normal function. Patients with severe hemophilia can have spontaneous bleeding of the ones with milder forms.Early detection of cases is critical for prevention of complications and timely therapy initiation. The diagnostic procedures consist of physical examination, coagulation tests, and analysis of factor VIII or factor IX activity in the blood. Genetic diagnosis can be of help in establishing the diagnosis, determining genetic mutations responsible for the disease, and assisting with the family counseling. Nevertheless, difficulties in the diagnosis may arise in cases where symptoms are inconclusive or no positive family history is established [1,3].
Pediatric hemophilia management has developed significantly since the introduction of various recombinant coagulation factors, long-acting drugs and non-factor treatment options. Prophylaxis treatment method is aimed at prevention of bleeding and maintaining joint function. Use of Emicizumab has improved prophylactic treatment options for hemophilia A patients, including those with factor VIII inhibitors. Yet, the need for specialized treatments, application, inhibitors’ development, costs of therapy, and long-term monitoring are still serious obstacles [1,4].
Successful management of cases implies involvement of all specialists, including pediatric hematologists, laboratory specialists, physiotherapists, nurses, dentists, etc. Education of families and patients, genetic counseling, suitable physical activities, and psychological support services are also very important components of his process.
Methodology
Relevant literature regarding hemophilia in children was acquired through targeted searches of biomedical databases like PubMed and reputable medical resources like the guidelines of the "World Federation of Hemophilia" (WFH) and the publications of "Centers for Disease Control and Prevention" (CDC). Search terms included “hemophilia in children,” “pediatric hemophilia,” “hemophilia A,” “hemophilia B,” “clinical manifestations,” “diagnostic process,” “factor replacement treatment,” “prophylactic treatment,” “emicizumab,” and “complications of hemophilia.”
The literature reviewed was selected based on its relevance to genetic factors, clinical picture, diagnostic procedures, complications, treatment, and management of pediatric hemophilia. Peer-reviewed articles, clinical studies, reviews, and professional guidelines were studied. Greater attention was paid to the articles dealing with prophylactic treatment, preservation of joints, appearance of inhibitors, and other achievements in therapy.
In total, the literature analyzed was considered qualitatively, and the articles were synthesized thematically, since no systematic review protocol was implemented, and no quantitative measurement of bias was conducted.
Result
The literature shows that hemophilia in kids is associated with a variety of bleeding symptoms, most of which have clinical severity dependent on residual coagulation factor activity. Hemophilia A, which results from factor VIII deficiency, is more prevalent than hemophilia B, which is due to factor IX deficiency. Both conditions can occur in infancy and childhood, but the age of diagnosis may differ depending on disease severity and previous bleeding history [1,2].
Clinical manifestations
Clinical features describing hemophilia include easy bruising after injury, bleeding after injury, presence of hematomas, and bleeding into various joints. Severe hemophilia includes spontaneous bleeding episodes, while mild types may remain undetected until trauma happens. Some kids may suffer from recurrent hemarthrosis (bleeding in joints) which leads to chronic inflammation of joints and impairment of their function. Intracranial bleeding represents the most dangerous type of bleeding [1].
Diagnosis and severity of the disease
The literature stresses the importance of taking clinical measures and confirming them by laboratory tests. Activated partial thromboplastin time may increase, while prothrombin time and platelet count remain within the normal range. While screening results are acceptable, mild hemophilia cannot be excluded under the same circumstances.
Treatment and prevention of bleeding
Replacement of missing coagulation factors before bleeding episodes takes place is one of the known ways of managing bleeding in children with severe hemophilia. Clinical studies prove the efficacy of prophylactic factor replacement in reducing bleeding episodes and preserving joint health compared to episodic factor replacement [4]. Prolonged living factor replacement products may also help to decrease susceptibility to bleeding in children.
Emicizumab has increased the potential for preventive treatment of patients with hemophilia A, even those with antibodies against factor VIII. The fact that emicizumab is given as a subcutaneous injection minimizes the problems associated with intravenous infusions. However, people may still experience breakthrough bleeding, requiring timely medical observation and right choice of appropriate hemostatic agents for such cases [1,5].
Complications and continuing challenges
The challenge remains in the form of inhibitors because it means that the same factor replacement therapy can be less effective. There are other important issues, including hemophilic arthropathy, cost of treatment, limited access to specialists, and different availability of preventive therapies. The literature suggests that managing hemophilia largely means providing an individualized treatment plan involving hemophilia specialists, physiotherapists, educating families, and monitoring ongoing bleeding events and joint statuses [1,5].
Discussion
In children, hemophilia is a significant clinical predicament because of the risk of bleeding, arthropathy, and other critical health issues. The literature highlights that early detection of hemophilia is vital for minimizing the morbidity associated with the condition. Even though significant innovations in replacement factor therapy and non-factor therapies have improved the management modalities, the outcome is still dependent on the severity of the disease, timing of diagnosis, treatment adherence, and availability of specialized care [1,2].
The clinical characteristics of hemophilia in children depend on the residual levels of clotting factor. Children with severe hemophilia experience spontaneous bleeding and recurrent hemarthrosis while the mild hemophilia is diagnosed after trauma or surgical interventions. These differences underline the importance of including hemophilia in the differential diagnosis of any case of unexplained bleeding in child patients with no family history of the disease. Specific factor activity testing is important for confirming the diagnosis of hemophilia as well as differentiation of hemophilia A from hemophilia B [1,3].
Hemophilic arthropathy is a vital concern in the long run. Frequent bleeding episodes into the joints may lead to inflammatory processes that will eventually harm the cartilage as well as adjacent tissues. The Joint Outcome Study indicated the benefits of prophylactic factor replacement among boys suffering from hemophilia A. In 93 percent of the subjects aged six that received prophylaxis, magnetic resonance imaging results showed normal joint structure in comparison to 55 percent of the studied boys who had enhanced episodic treatment [4]. Thus, this evidence indicates that it is essential to initiate preventive treatment on time rather than wait for bleeding and treat the condition only after it occurs.
Standard factor replacement therapy is still an important part of the treatment process. Administration of regular prophylactic therapy decreases the bleeding risk and ensures that the function of the joint remains undamaged; however, intravenous factor injection, affordability of treatment, and unique pharmacokinetic profiles make the process complicated. The development of emicizumab changes the hemophilia A management process significantly. This bispecific antibody mimicking the function of activated factor VIII serves a different mechanism of the blood coagulation process and is delivered subcutaneously.
The development of inhibitors continues to be a significant therapeutic obstacle in severe hemophilia A. These antibodies may hinder the effectiveness of the infusion of factor concentrates and make the management of bleeding episodes harder. Treating such cases may call for the use of bypassing agents governed by specialized healthcare providers, non-factor prophylaxis, or immune tolerance induction for selected patients. That means that such treatment must be tailored for a specific patient taking into account all circumstances [1].
In spite of the advances in therapies, considerable issues persist. Lack of access to factor concentrates or specialized laboratories as well as other medical services may lead to delayed diagnosis and possible complications. Hence, enhancing the healthcare infrastructure, improving referral pathways and guaranteeing access to medical services is essential.
Gene therapy and other current methods may have a substantial impact on treatment methods. However, their suitability for kids must be approached with caution due to the possible risks.
Conclusion
Hemophilia in children is a major hereditary bleeding disorder for which timely diagnosis, proper treatment, and permanent medical care is necessary to prevent life-threatening complications. Proper diagnosis through clinical examination and specific coagulation factor tests together with timely initiation of prophylactic treatment can lead to reduction of bleeding episodes, thus preserving the joints’ health. Due to the recent advances in the field of factor replacement therapy and non-factor therapies of hemophilia, including emicizumab for hemophilia A, the opportunities for preventative treatment have increased. Nonetheless, the emergence of inhibitors, cost of treatment, and unequal access to specialized medicine remain pressing issues. Comprehensive multidisciplinary approach including family education, genetic counseling, and regular follow up for hemophiliacs is important for improving their prognosis and quality of life. More studies are necessary to examine new methods of treatment, increase possibility of providing effective therapy, and deal with existing issues related to treatment of hemophiliac patients.
References
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046.
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672.
Centers for Disease Control and Prevention. Diagnosing Hemophilia [Internet]. Atlanta (GA): CDC. Available from: https://www.cdc.gov/hemophilia/testing/index.html
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659.
Le Quellec S. Clinical evidence and safety profile of emicizumab for the management of children with hemophilia A. Drug Des Devel Ther. 2020;14:469–481. doi:10.2147/DDDT.S167731.
Lai J, Hough C, Tarrant J, Lillicrap D. Development of inhibitors in hemophilia A: an illustrated review. Res Pract Thromb Haemost. 2020;4(5):752–760. doi:10.1002/rth2.12335.
Mancuso ME, Mahlangu JN, Pipe SW. Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia. 2021;27(6):889–896. doi:10.1111/hae.14412.
Centers for Disease Control and Prevention. Treatment of Hemophilia [Internet]. Atlanta (GA): CDC. Available from: https://www.cdc.gov/hemophilia/treatment/index.html
Manco-Johnson MJ, Soucie JM, Gill JC; Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–2374. doi:10.1182/blood-2016-02-683169.
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 3rd ed. Montreal: World Federation of Hemophilia; 2020. Available from: https://guidelines.wfh.org/guidelines/